Soligenix Enters Q4 With Multiple Catalysts in Play

New York, New York–(Newsfile Corp. – October 13, 2022) – PCG Digital — Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentially transformational year in 2023.

Following its successful Phase 3 clinical trial evaluating HyBryte (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL), Soligenix is preparing to file a New Drug Application (NDA) with the FDA. HyBryte™ will potentially be a first-in-class treatment for CTCL, a rare skin cancer.

The company’s Public Health Solutions business segment is also making strong inroads, as it advances a heat stable vaccine platform that has the potential to prevent and manage future pandemics.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140337